Overall, average survival time was numerically, but not significantly, longer in the combined treatment group versus the bevacizumab-only group 10.1 months versus 9.7 months, respectively. It may also limit the degree of radiation-induced injury when radiation is repeated, such as in this study," Raizer said. "Bevacizumab is an anti-angiogenic medication, designed to prevent blood vessel growth in tumors. Patients were then randomly assigned to receive reirradiation and bevacizumab every two weeks or bevacizumab alone until tumor progression was detected. In the current phase II clinical trial, 170 individuals with recurrent glioblastoma greater or equal to six months after completion of initial radiation and chemotherapy were enrolled. One option is for patients to receive repeat radiation, also known as reirradiation. In the case of recurrence, treatment options are limited and better treatments are needed. In addition to chemotherapy and other therapeutic interventions, most patients with glioblastoma receive radiation therapy at the time of diagnosis, except in some cases for those patients who are 70 years and older.
Unfortunately, most patients with glioblastoma will experience recurrence, and while the timing of recurrence varies between patients, most will recur on average eight to 12 months after initial diagnosis. According to the National Brain Tumor Society, the five-year survival rate for glioblastoma patients is 6.8 percent, and the average length of survival for glioblastoma patients is eight months. Glioblastoma accounts for nearly half of all primary malignant brain tumors. Jeffrey Raizer, MD, adjunct professor in the Ken and Ruth Davee Department of Neurology's Division of Neuro-Oncology, was a co-author of the study.
0 kommentar(er)
